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A B S T R A C T
Purpose
The Cancer Esophagus Geﬁtinib trial demonstrated improved progression-free survival with the
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor geﬁtinib relative to placebo in
patients with advanced esophageal cancer who had disease progression after chemotherapy. Rapid
and durable responses were observed in a minority of patients. We hypothesized that genetic
aberration of the EGFR pathway would identify patients beneﬁtting from geﬁtinib.
Methods
A prespeciﬁed, blinded molecular analysis of Cancer Esophagus Geﬁtinib trial tumors was con-
ducted to compare efﬁcacy of geﬁtinib with that of placebo according to EGFR copy number gain
(CNG) and EGFR, KRAS, BRAF, and PIK3CA mutation status. EGFR CNG was determined by
ﬂuorescent in situ hybridization (FISH) using prespeciﬁed criteria and EGFR FISH-positive status was
deﬁned as high polysomy or ampliﬁcation.
Results
Biomarker data were available for 340 patients. In EGFR FISH-positive tumors (20.2%), overall
survival was improved with geﬁtinib compared with placebo (hazard ratio [HR] for death, 0.59; 95%
CI, 0.35 to 1.00; P = .05). In EGFR FISH-negative tumors, there was no difference in overall survival
with geﬁtinib compared with placebo (HR for death, 0.90; 95% CI, 0.69 to 1.18; P = .46). Patients
with EGFR ampliﬁcation (7.2%) gained greatest beneﬁt from geﬁtinib (HR for death, 0.21; 95% CI,
0.07 to 0.64; P = .006). There was no difference in overall survival for geﬁtinib versus placebo for
patients with EGFR, KRAS, BRAF, and PIK3CA mutations, or for any mutation versus none.
Conclusion
EGFR CNG assessed by FISH appears to identify a subgroup of patients with esophageal cancer
who may beneﬁt from geﬁtinib as a second-line treatment. Results of this study suggest that anti-
EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR
FISH-positive and, in particular, EGFR-ampliﬁed esophageal cancer.
J Clin Oncol 35:2279-2287. © 2017 by American Society of Clinical Oncology
INTRODUCTION
An estimated 455,000 individuals worldwide are
diagnosed annually with esophageal cancer.1,2In
North America, Northern and Western Europe,
and Oceania, the incidence of esophageal ade-
nocarcinoma has risen in the last four decades
and is now the predominant histologic subtype.2
Squamous cell carcinoma of the esophagus re-
mains more common globally and in south-
eastern and central Asia.2
Five-year survival is only 19%.3 Most patients
present with advanced disease not amenable to
curative therapy.4 Systemic treatment with cyto-
toxic chemotherapy provides palliative beneﬁts;
however, current treatment options are of more
limited effectiveness following progression after
ﬁrst-line therapy.4,5 Phase III randomized trials
of second- or third-line treatment in gastric and/or
esophagogastric junction adenocarcinomas have
demonstrated beneﬁt from apatinib, irinotecan,
ramucurimab, and ramucurimab combined with
paclitaxel.6-12 Some caution is needed in extrapo-
lating results for gastroesophageal adenocarcinomas
from different sites, because although molecular
analysis suggests that esophagogastric junction and
more-proximal esophageal adenocarcinomas are
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biologically similar, more-distal gastric adenocarcinomas appear
distinct.13 There is more limited evidence supporting the use of
second-line therapy in esophageal squamous cell carcinoma.5,14
The Cancer Esophagus Geﬁtinib (COG) trial is the only
randomized phase III study of second-line therapy speciﬁcally in
chemoresistant esophageal cancer, including adenocarcinoma and
squamous cell carcinoma.15 In the COG trial, 450 patients were
randomly assigned to the epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) geﬁtinib or placebo. Progression-free
survival (PFS) and patient-reported outcomes (PROs) were im-
proved for geﬁtinib, reﬂecting the occurrence of rapid and durable
responses to geﬁtinib in a minority subset of patients. Beneﬁt from
geﬁtinib occurred in adenocarcinomas and squamous cell carci-
nomas to an equal extent.
We hypothesized that the geﬁtinib-responsive subgroup of
patients were a subset for whom EGFR signaling was an important
driver. Avariety of different EGFR signaling abnormalities have been
described in esophageal cancer, including copy number gain (CNG)
of EGFR.16-20 Study results suggest that chromosomal instability is
an early and frequent feature of esophageal cancer pathogenesis, and
somatic copy number alterations occur frequently in esophageal
adenocarcinoma and squamous cell carcinoma.19-24 Therefore, we
hypothesized that EGFR signaling was a key pathogenic driver in the
minority subset of esophageal cancers with EGFR CNG, and that
these patients would beneﬁt from geﬁtinib.
Accordingly, we investigated EGFR signaling pathway ab-
normalities in an adequately powered, prospectively collected
cohort of tumor specimens from patients in the COG trial, with
prespeciﬁed biomarker assays undertaken blind to treatment al-
location and outcome, and a statistical analysis plan that was
formulated before biomarker assay results were available.
METHODS
Study Design and Oversight
The COG trial (ISRCTN29580179) compared efﬁcacy of 500 mg of
geﬁtinib daily with that of placebo in patients with esophageal cancer who
had disease progression after chemotherapy.15 Participants were recruited
from 48 centers in the United Kingdom and randomly assigned (1:1) to
geﬁtinib or matching placebo by simple randomization with no stratiﬁ-
cation factors. The primary end point was overall survival (OS). Secondary
end points were PFS, disease control rate (DCR; calculated as Response
Evaluation Criteria in Solid Tumors [RECIST] version 1.1 partial response
plus complete response plus stable disease at 8 weeks), and PROs.15
Formalin-ﬁxed parafﬁn-embedded tumor tissues were prospectively col-
lected for a translational substudy of the COG trial, TRANSCOG
(ISRCTN32435732).
The TRANSCOG study was undertaken in accordance with the
protocol and was approved by the National Research Ethics Service
Committee (Reference 11/0372/AL). All handling and assays of tumor
specimens were performed according to good clinical laboratory standards
in diagnostically accredited (ISO15189:2012) laboratories. All molecular
analysis was undertaken blind to treatment and clinical outcome data.
A reporting recommendations for tumor marker prognostic studies
(REMARK)25 compliance checklist is provided (Data Supplement).
Tumor Specimens
Archived formalin-ﬁxed parafﬁn-embedded tumor specimens were
collected and processed according to a prespeciﬁed standard operating
procedure. Central pathology review was performed to conﬁrm histologic
diagnosis and assess tumor cellularity. Tumor tissue sections (4 mm) were
prepared for EGFR ﬂuorescent in situ hybridization (FISH). DNA was
extracted using a standard dewaxing, tissue digestion, and phenol/
chloroform methodology with macrodissection to enrich for tumor in
specimens with , 50% tumor cellularity.
EGFR Gene Copy Number Analysis
EGFR copy number analysis was by FISH and tumors were classiﬁed
using the 6-point scale described previously.26 Tumors scoring 5 (high
polysomy) or 6 (ampliﬁcation) were classiﬁed as having EGFR high CNG
and deﬁned as EGFR FISH positive; tumors scoring 1 to 4 were classiﬁed as
having no or low CNG and deﬁned as EGFR FISH negative26 (Data
Supplement). Analysis was performed by two independent scorers in
a laboratory with Clinical Pathology Accreditation. Discordance led to
further analysis by a third independent scorer. The testing plan and
methodology were prespeciﬁed.
Mutational Analysis
Methods for each mutation were optimized for sensitivity and re-
liability. The ﬁnal testing plan and methodology were prespeciﬁed. KRAS
mutation was analyzed by pyrosequencing using primers and probes
speciﬁcally designed for codons 12, 13, and 61. EGFR, PIK3CA, BRAF
V600E, andmutations were detected by Sanger sequencing as a ﬁrst option;
failed samples were analyzed using COBAS EGFR PIK3CA and BRAF
V600E mutation testing kits (Roche Molecular Systems, Branchburg, NJ).
Deletions in exon 19 of EGFR were detected by fragment length analysis.
Details are available in the Data Supplement.
Statistical Analysis
The statistical analysis plan was prespeciﬁed before molecular results
were available. The primary objective was to compare the effect of geﬁtinib
with that of placebo in EGFR FISH-positive and -negative patients, and
patients with and without EGFR, KRAS, BRAF, and PIK3CA mutations in
the primary analysis the COG trial study population.15 The primary end
point was OS; secondary end points were PFS, DCR (calculated as RECIST
version 1.1 partial response plus complete response plus stable disease at
8 weeks), and PROs. We assumed that tumor samples would be available
from. 300 patients. Considering a = .05, the accrual of tumor tissues over
the 30 months of the COG study, a 12-month minimum follow-up,
a hazard ratio (HR) of 0.50 favoring geﬁtinib in biomarker subgroups,
and a median survival of 3 months in placebo-treated patients, and then
assuming equal representation of geﬁtinib or placebo in tested samples,
a predictive biomarker-deﬁned subgroup of 10% within the geﬁtinib arm
only comparing positive with negative biomarker groups would provide
a power of 0.73, 15% would provide a power of 0.88, and 20% would
provide a power of 0.93.
The power to compare within a biomarker-positive group between
geﬁtinib- and placebo-treated patients was reduced because of the small
sample size expected in these groups (biomarker positive: 10%, power of
0.45; 15%, power of 0.61; and 20%, power of 0.72).The study was not
powered to test the interaction between biomarkers and treatment formally.
To estimate the treatment effects of geﬁtinib, we used the Cox
proportional hazardmodel to compare outcomes in geﬁtinib with placebo
in each biomarker-positive and -negative subgroup. The proportional
hazard assumption was tested by examining the log cumulative hazards
plot and Schoenfeld residual plot, and no signiﬁcant deviations were
found. Comparisons between biomarker status and DCR, between bio-
marker status and PROs, and between biomarker status and clinical
variables were performed using a x2 test or Fisher exact test, as appro-
priate. In the biomarker analysis, multiple testing was not adjusted for. To
avoid errors for multiple testing in PRO analysis, biomarker status was
investigated only for the four PROs of particular importance prespeciﬁed in
the COG trial.15
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The signiﬁcance level for all statistical outcomes was prespeciﬁed as
0.05 and 95% CIs were calculated. The deﬁnitions of OS, PFS, and DCR,
andmethods for health-related quality of life (HRQL) assessment for PROs
are detailed in the COG trial primary publication.15
RESULTS
Patients
Tumor specimens were available from 340 of 450 patients
(76%) in the COG study. Overall, 292 patients (65%) had tumor
evaluable for EGFR CNG by FISH and 326 patients (72%) had
tumor evaluable for EGFR, KRAS, PIK3CA, and BRAF mutation
(Fig 1). The mutation analysis comprised EGFR exon 19 deletion in
254 patients, EGFR exons 18 to 21 in 223 patients, KRAS codon 12
and 13 in 268 patients, KRAS codon 61 in 287 patients, PIK3CA
exon 9 in 267 patients and exon 20 in 273 patients, and BRAF
V600E in 267 patients.
A total of 165 patients with EGFR FISH results completed
HRQL questionnaires at baseline and 4 weeks, and 88 completed
them at baseline and 8 weeks; these were included in the PRO
analysis (Data Supplement).
The cohorts of patients evaluable for EGFR CNG, mutations,
and PROs were not different than the COG trial cohort in terms of
clinical features, OS, PFS, and baseline HRQL, and clinical features
were balanced in the geﬁtinib and placebo groups (Table 1; Data
Supplement).
Tumors from 59 patients were EGFR FISH positive (59 of 292
patients; 20.2%), with high polysomy in 13% (38 of 292) and
ampliﬁcation in 7.2% (21 of 292 patients; Data Supplement). No
EGFRmutations were detected. KRAS codon 12 and 13 mutations
were found in 4.1% of patients (11 of 268), KRAS codon 61
mutations in 1.1% (three of 261), PIK3CA exon 9 mutations in
3.4% (nine of 267), PIK3CA exon 20 mutations in 0.7% (two of
273), and BRAF V600E in 0.4% (one of 267). There was no
signiﬁcant association between EGFR FISH (Table 2) or any
mutation (Data Supplement) and clinical features.
Efficacy According to Tumor EGFR Gene Copy Number
Status
The DCR was higher in patients with EGFR FISH-positive
tumors who received geﬁtinib compared with those who received
placebo: 37% (11 of 30 patients; 11 patients with stable disease) for
geﬁtinib versus 14% (four of 29 for placebo; P = .04). PFS and OS
were also improved in EGFR FISH-positive patients who received
geﬁtinib compared with those who received placebo (PFS HR, 0.55
[95% CI, 0.32 to 0.95], P = .03 for geﬁtinib v placebo-treated
patients; and OS HR, 0.59 [95% CI, 0.35 to 1.00], P = .05 for
geﬁtinib v placebo-treated patients; Fig 2). OS in EGFR FISH-
positive patients treated with geﬁtinib versus those treated with
placebo at 3, 6, 9, and 12 months was 69% versus 64%, 38% versus
14%, 27% versus 5%, and 13% versus 0%, respectively.
A multivariate Cox proportional hazards analysis (n = 277 for
PFS and n = 278 for OS) was performed (Data Supplement)
adjusted for performance status, prior treatment, body mass index,
histology, disease site, age, and sex. In this analysis, PFS remained
signiﬁcant for beneﬁt of geﬁtinib compared with placebo in EGFR
FISH-positive patients (HR, 0.42; 95%CI, 0.22 to 0.81; P = .01) but
not OS (HR, 0.57; 95% CI, 0.30 to 1.06; P = .08). None of the
variables were signiﬁcantly associated with PFS or OS in the
multivariate analysis in EGFR FISH-positive patients.
A post hoc analysis suggested that patients with EGFR am-
pliﬁcation (7.2% of patients) gained greater beneﬁt from geﬁtinib
than those with high polysomy (Figs 2 and 3; Data Supplement).
DCR was also higher in EGFR FISH-negative patients who
received geﬁtinib compared with those who received placebo, but
DCR was greater in EGFR FISH-positive patients (25% [29 of 115
patients receiving geﬁtinib], three partial responses, and 26 stable
disease) versus 14% for placebo (P = .06). In EGFR FISH-negative
patients, PFS (HR, 0.87; 95% CI, 0.66 to 1.12; P = .28), and OS (HR,
0.90; 95% CI, 0.69 to 1.18; P = .46) were not different for geﬁtinib
compared with that of placebo (Fig 2). OS in EGFR FISH-negative
patients treated with geﬁtinib versus placebo at 3, 6, 9, and 12months
was 61% versus 46%, 33% versus 29%, 16% versus 22%, and 8%
versus 14%, respectively. In the multivariate analysis, PFS and OS
were not signiﬁcantly different for geﬁtinib compared to placebo in
EGFR FISH-negative patients, but performance status, prior treat-
ment, and site of tumor were signiﬁcantly associated with OS and
PFS, respectively (Data Supplement).
Because of small patient numbers, differences in the COG
trial-prespeciﬁed HRQL domains at 4 weeks and 8 weeks com-
pared with baseline were not signiﬁcantly different between the
geﬁtinib and placebo groups for EGFR FISH-positive and -negative
patients (Data Supplement). However in EGFR FISH-positive patients,
Randomly assigned  patients in COG study
(N = 450)
Patients  with FFPE tumor tissue
available for analysis
(n = 340) 
Patients evaluable for EGFR,
KRAS, BRAF, and
PIK3CA mutations
(n = 326)
Patients evaluable for
EGFR CNG
(n = 295)
Excluded for 
insufficient DNA quality
(n = 14)
Excluded for 
insufficient tissue
(n = 45)
Received
gefitinib
(n = 146) 
Received
placebo
(n = 149)
Received
gefitinib
(n = 161)
Received
placebo
(n = 165)
Excluded
No tumor tissue available
Withdrew consent before
    treatment
(n = 110)
(n = 109)
(n = 1)
Fig 1. Patient and specimen ﬂow in the COG and translational COG (TRANS-
COG) trials. CNG, copy number gain; COG, Cancer Esophagus Geﬁtinib; EGFR,
epidermal growth factor receptor; FFPE, formalin-ﬁxed parafﬁn-embedded.
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all prespeciﬁed HRQL domains improved with geﬁtinib compared
with placebo, in contrast to an observed deterioration or lesser im-
provement seen in EGFR FISH-negative patients (Fig 4). At 8 weeks,
mean scores for global quality of life (+10.7) and difﬁculty eating
(220.8) were improved beyond the 8-point difference considered to be
of clinical importance with geﬁtinib compared with placebo in EGFR
FISH-positive patients. However, none of the prespeciﬁed HRQL
domains were changed$ 8 in EGFR FISH-negative patients at 8 weeks
(Data Supplement).
Efficacy According to Tumor Mutation Status
There was no signiﬁcant difference in DCR, PFS, OS, or PROs
for KRAS codon 12 and 13, KRAS codon 61, PIK3CA exon 9 or 20,
or BRAF V600E mutations, or the presence of any mutation versus
none (Data Supplement).
DISCUSSION
In the COG trial, 450 patients with esophageal adenocarcinoma or
squamous cell carcinoma progressive after previous chemotherapy
were randomly assigned to treatment with geﬁtinib or placebo.
Improved DCR, PFS, and PROs were observed for geﬁtinib com-
pared with placebo, reﬂecting rapid and durable beneﬁts occurring
in a minority subgroup.15 Geﬁtinib was well tolerated and, although
objective responses were rare, when observed, they invariably
occurred rapidly within 4 weeks of starting geﬁtinib. However, it
is clear that most patients do not beneﬁt from geﬁtinib. Iden-
tiﬁcation of a predictive biomarker for patients who receive
beneﬁt from geﬁtinib would enable a more accurate selection of
patients for treatments and prevent futile treatment in those
patients who are unlikely to beneﬁt.
Based on the outcome of the COG trial, we hypothesized that
there was a subgroup of patients whose tumors were driven by
EGFR signaling and who, accordingly, beneﬁtted from treatment
with geﬁtinib. This is analogous to non–small-cell lung cancer and
colorectal adenocarcinoma in which EGFR mutation and KRAS
mutation, respectively, have provided useful predictive biomarker
tests and allowed subgroups to be deﬁned as responsive to anti-
EGFR therapies.27,28 We aimed to determine if analysis of EGFR
signaling pathway abnormalities in esophageal carcinoma would
similarly predict beneﬁt from geﬁtinib.
EGFR FISH-positive patients whose esophageal cancers had
EGFR CNG deﬁned as high polysomy or ampliﬁcation by FISH,
had improved DCR, PFS, OS, and PROs when treated with
geﬁtinib compared with placebo. In contrast, EGFR FISH-negative
patients had improved DCR, but this did not translate into im-
proved PFS, OS, or PROs. This suggests that patients with EGFR
FISH positive tumors have increased survival, as well as improved
HRQL, with geﬁtinib, which is important in this clinical setting of
limited life expectancy. Our post-hoc analysis suggests that the
Table 1. Clinical Features of the Patients Evaluable for EGFR Copy Number Gain by FISH
Clinical Feature
COG Trial Cohort (N = 449)* EGFR FISH Cohort (N = 292)
Placebo (n = 225) Geﬁtinib (n = 224) Placebo (n = 147) Geﬁtinib (n = 145)
Age at assignment, years, mean (SD) 64.5 (9.4) 63.7 (9.6) 64.5 (9.4) 64.1 (9.2)
Sex, No. (%)
Male 189 (84.0) 183 (81.7) 124 (84.4) 118 (81.4)
Female 36 (16.0) 41 (18.3) 23 (15.7) 27 (18.6)
Time since diagnosis, years, median (IQR) 0.92 (0.60, 1.47) 0.96 (0.62, 1.45) 0.86 (0.57, 1.48) 0.95 (0.59, 1.38)
Original diagnosis, No. (%)
Adenocarcinoma 168 (74.7) 173 (77.2) 102 (69.4) 112 (77.2)
Squamous 56 (24.9) 50 (22.3) 44 (29.9) 32 (22.1)
Undifferentiated 1 (0.4) 1 (0.4) 1 (0.7) 1 (0.7)
Disease site, No. (%)
Esophageal 181 (80.4) 171 (76.3) 120 (81.6) 109 (75.2)
Type I junctional 21 (9.3) 26 (11.6) 12 (8.2) 17 (11.7)
Type II junctional 23 (10.2) 27 (12.1) 15 (10.2) 19 (13.1)
Performance status, No. (%)
0 56 (24.9) 57 (25.5) 33 (22.5) 36 (24.8)
1 125 (55.6) 117 (52.2) 86 (58.5) 75 (51.7)
2 44 (19.6) 50 (22.3) 28 (19.1) 34 (23.5)
Previous treatments, No. (%)
0 1 (0.4) 0 1 (0.7) 0
1 137 (60.9) 137 (61.2) 95 (64.6) 94 (64.8)
2 75 (33.3) 78 (34.8) 41 (27.9) 48 (33.1)
3 12 (5.3) 9 (4.0) 10 (6.8) 3 (2.1)
BMI, kg/m2, mean (SD); No. 24.01 (4.77); 212 24.01 (4.94); 214 24.0 (4.18); 141 24.1 (4.4); 139
BMI grouped, No. (%)
, 18.0 24 (10.7) 24 (10.7) 16 (10.9) 13 (9.0)
18.0-24.9 117 (52.0) 113 (50.5) 77 (52.4) 73 (50.3)
25.0-29.9 43 (19.1) 55 (24.6) 31 (21.1) 40 (27.6)
$ 30 28 (12.4) 22 (9.8) 17 (11.6) 13 (9.0)
Missing 13 (5.8) 10 (4.5) 6 (4.1) 6 (4.1)
Abbreviations: BMI, body mass index; COG, COG, Cancer Esophagus Geﬁtinib; EGFR, epidermal growth factor receptor; FISH, ﬂuorescent in situ hybridization; IQR,
interquartile range; SD, standard deviation.
*One patient in the geﬁtinib arm withdrew consent shortly after being randomly assigned and is excluded from all analyses.
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beneﬁt of geﬁtinib is greater in those with EGFR-ampliﬁed tumors
than with high polysomy tumors. Our study was not powered to
investigate these subgroups, and additional investigation is needed
to validate this observation. However, this ﬁnding is consistent
with results for anti-EGFR and other targeted therapies in other
tumor types.29-31 Overall, our results suggest it is likely there is
a greater beneﬁt from geﬁtinib in EGFR-ampliﬁed esophageal
cancers compared with those with high polysomy.
Our ﬁndings are supported by the report of high sensitivity to
geﬁtinib in a primary cell line derived from a patient with
esophageal adenocarcinoma with EGFR high polysomy.32 In ad-
dition, a single-arm phase II trial of the EGFR TKI icotinib in
esophageal squamous cell carcinoma with EGFR CNG determined
by FISH or strongly positive EGFR immunohistochemistry re-
ported a DCR of 46%.33
This suggests that EGFR FISH identiﬁes those patients with
esophageal cancer whose tumors are driven by EGFR signaling and
for whom inhibition of EGFR confers beneﬁt. Investigating the
impact of EGFR FISH positivity on sensitivity to EGFR inhibitors
other than geﬁtinib would test this hypothesis. Similar to HER2 in
gastroesophageal adenocarcinoma, EGFR TKIs and monoclonal
antibodies may have different impacts in EGFR FISH-positive
patients.34,35 Not all EGFR FISH-positive patients beneﬁt from
geﬁtinib and coampliﬁcation of other receptor tyrosine kinases (RTKs)
and/or downstream signaling pathways may also be important
determinants of clinical beneﬁt.36,37 RTK pathway copy number
proﬁling could improve predictive accuracy and guide person-
alized use of EGFR and other RTK inhibitors.
To our knowledge, there have been no previous ran-
domized trials of second-line therapy in esophageal cancer
including adenocarcinomas and squamous cell carcinomas.
However, the PFS and OS beneﬁts from geﬁtinib compared with
placebo in EGFR FISH-positive patients that we observed is of
a similar proportion to those in randomized studies versus
placebo or supportive care only for other second-line therapies
in gastric and gastroesophageal junction adenocarcinoma,
including apatinib, regorafenib, docetaxel, irinotecan, and
ramucurimab.7-12,38 In comparison with docetaxel and irino-
tecan, the toxicity of geﬁtinib is preferable. The toxicity of
geﬁtinib is similar overall to that of ramucurimab, apatinib, or
regorafenib, but because there are no predictive biomarkers for
these agents, the use of geﬁtinib in patients selected by EGFR
FISH status represents an alternative with increased clinical and
cost effectiveness.
The use of next-generation sequencing would have provided
higher sensitivity for subclonal mutations. However, the low
frequency of mutations detected in our study, in contrast to EGFR
CNG, which predicts geﬁtinib beneﬁt, is consistent with other
reports and genome landscaping studies that demonstrate pre-
dominant copy number changes.18-20,36 In adenocarcinoma,
Table 2. Association of Clinical Features and EGFR Copy Number Gain Status
Clinical Feature EGFR Copy Number Gain (N = 59) EGFR No Copy Number Gain (N = 233) P
Age at assignment, years, mean (SD) 63.9 (8.3) 64.4 (9.5) .85
Sex, No. (%) .97
Male 49 (83.1) 193 (82.8)
Female 10 (17.0) 40 (17.2)
Time since diagnosis, years median (IQR); No. 0.95 (0.51, 1.27); 57 0.90 (0.60, 1.45); 231 .10
Original diagnosis, No. (%) .69
Adenocarcinoma 44 (74.6)* 170 (73.0)
Squamous 14 (23.7)† 62 (26.6)
Undifferentiated 1 (1.7)‡ 1 (0.4)
Disease site, No. (%) .50
Esophageal 46 (78.0) 183 (78.5)
Type I junctional 4 (6.8) 25 (10.7)
Type II junctional 9 (15.3) 25 (10.7)
Performance status, No. (%) .27
0 12 (20.3) 57 (24.5)
1 30 (50.9) 131 (56.2)
2 17 (28.8) 45 (19.3)
Previous treatments, No. (%) .90
0 0 1 (0.4)
1 39 (66.1) 150 (64.4)
2 18 (30.5) 71 (30.5)
3 2 (3.4) 11 (4.7)
BMI, kg/m2, mean (SD); No. 23.7 (4.5); 55 24.1 (4.6); 225 .55
BMI grouped, No. (%) .74
, 18.0 4 (6.8) 25 (10.7)
18.0-24.9 33 (55.9) 117 (50.2)
25.0-29.9 14 (23.7) 57 (24.5)
$ 30 4 (6.8) 26 (11.2)
Missing 4 (6.8) 8 (3.4)
Abbreviations: BMI, body mass index; EGFR, epidermal growth factor receptor; IQR, interquartile range; SD, standard deviation.
*Twenty-nine of 44 EGFR ﬂuorescent in situ hybridization (FISH) –positive adenocarcinomas (65.9%) had EGFR high polysomy and 15 of 44 (34.1%) had EGFR
ampliﬁcation.
†Fourteen of 14 EGFR FISH-positive squamous cell carcinomas (64.2%) had EGFR high polysomy and ﬁve of 14 (35.8%) had EGFR ampliﬁcation.
‡The EGFR FISH-positive undifferentiated carcinoma was EGFR ampliﬁed.
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Fig 2. Kaplan-Meier estimates of PFS and OS according to treatment group. (A) OS in patients positive for EGFR by ﬂuorescent in situ hybridization (FISH). (B) OS in EGFR
FISH-negative patients. (C) PFS in EGFR FISH-positive patients. (D) PFS in EGFR FISH-negative patients. (E) OS in EGFR-ampliﬁed patients (FISH category 6). (F) PFS in
EGFR-ampliﬁed patients (FISH category 6). EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
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chromosomal instability leading to structural aneuploidy includ-
ing CNGs of oncogenes such as EGFR is common.17-20,23,36 In our
analysis, we found no signiﬁcant difference in the frequency of EGFR
CNG between adenocarcinomas and squamous cell carcinomas.
There was insufﬁcient tissue available to analyze EGFR protein
expression. In esophageal cancer, EGFR FISH-positive tumors
almost invariably overexpress EGFR by immunohistochemistry,
but up to 50% of EGFR FISH-negative tumors also strongly
-4
-2
0
2
4
6
8
10
12
 4 weeks 8 weeks
Global Quality of Life EORTC C30
G
ef
it
in
ib
 B
et
te
r
M
ea
n 
Di
ffe
re
nc
e 
Co
m
pa
re
d
to
 B
as
el
in
e
A
M
ea
n 
Di
ffe
re
nc
e 
Co
m
pa
re
d
to
 B
as
el
in
e
-12
-10
-8
-6
-4
-2
0
2
4
6
 4 weeks 8 weeks
Odynophagia
G
ef
it
in
ib
 B
et
te
r
C
M
ea
n 
Di
ffe
re
nc
e 
Co
m
pa
re
d
to
 B
as
el
in
e
-25
-20
-15
-10
-5
0
5
10
4 weeks 8 weeks
Difficulty Eating 
G
ef
it
in
ib
 B
et
te
r
B
EGFR CNG negative
EGFR CNG positive
M
ea
n 
Di
ffe
re
nc
e 
Co
m
pa
re
d
to
 B
as
el
in
e
-5
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
 4 weeks 8 weeks
Dysphagia
G
ef
it
in
ib
 B
et
te
r
D
EGFR CNG negative
EGFR CNG positive
P
la
ce
b
o
 B
et
te
r
EGFR CNG negative
EGFR CNG positive
P
la
ce
b
o
 B
et
te
r
EGFR CNG negative
EGFR CNG positive
P
la
ce
b
o
 B
et
te
r
Fig 4. Patient-reported outcomes. (A) Global quality of life. (B) Difﬁculty eating. (C) Odynophagia. (D) Dysphagia. CNG, copy number gain; EGFR, epidermal growth factor
receptor; FISH, ﬂuorescent in situ hybridization.
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overexpress EGFR protein.39,40 Together with our demonstration
of lack of beneﬁt from geﬁtinib in EGFR FISH-negative patients,
this suggests that EGFR FISH may be more a reliable predictive
biomarker than EGFR immunohistochemistry, although this needs
to be conﬁrmed by additional investigation.
This study was retrospective and, therefore, subject to
limitations. The results of EGFR CNG and the mutation analysis
may not be representative of the intention-to-treat population
from the original randomization. However, the cohort of patients
tested did not show signiﬁcant differences in clinical features
compared with the intention-to-treat population. Furthermore,
molecular testing and analysis were hypothesis driven, performed
to diagnostic standard in a reference laboratory with clinical
pathology accreditation, blind to patient treatment and out-
comes, had a prospectively determined statistical analysis plan
formulated before molecular results were available, and used data
from a large, randomized controlled trial. Therefore, this study
robustly evaluated EGFR CNG determined by FISH as a pre-
dictive biomarker.
In conclusion, EGFR FISH appears to predict a beneﬁt from
geﬁtinib in patients with esophageal cancer whose disease has
progressed after previous chemotherapy. The role of geﬁtinib and
other anti-EGFR therapies should be explored in prospective
clinical trials in different settings in EGFR FISH-positive esoph-
ageal cancer, particularly in EGFR-ampliﬁed tumors, in which the
impact of these agents is likely to be greatest.
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